Animal study · mice
SS-31 aided functional recovery after spinal cord injury in mice
Checked against the paper Animal studyPublished by PepVault
The takeaway
This mouse study adds early lab evidence that SS-31 may support recovery after spinal cord injury, but it is not a human result.
- Kind
- Animal study
- Studied in
- Mice
- Published
- 2023
- Journal
- J Neuroinflammation
What they tested
The team wanted to know whether SS-31 (elamipretide) helps mice regain function after a spinal cord injury, and through which pathway.
How the study was done
A lab study in mice given a contusion injury to the spinal cord, with function tracked by the Basso Mouse Scale, footprint assessment and an inclined plane test, and the cord tissue examined with stains and protein tests. The team also used AAV vectors to raise Pla2g4A levels and gave asiatic acid, a p38-MAPK agonist, to probe how SS-31 worked.

What they found
In mice with spinal cord injury, SS-31 lowered pyroptosis, a form of inflammatory cell death, boosted autophagy, the cell's own cleanup process, and reduced lysosomal membrane permeabilization, a leak in the cell's waste compartments. Tests that raised Pla2g4A levels in the mice indicated that SS-31 had these effects by blocking phosphorylation of cPLA2. The authors conclude that SS-31 supported functional recovery in mice partly through these effects.
What it doesn’t show
This was work in mice, so it does not show that SS-31 helps people with spinal cord injury. It tested one type of injury model.
The paper
Zhang et al. Elamipretide alleviates pyroptosis in traumatically injured spinal cord by inhibiting cPLA2-induced lysosomal membrane permeabilization. J Neuroinflammation. 2023.
The compound
More studies on SS-31
- SS-31 (elamipretide) eye drops missed main vision goal in LHON trialRandomized trial · people · 2024
- SS-31: wearable data grouped responders with 100% accuracyRandomized trial · people · 2023
- SS-31: no 12-week benefit, walk gains by 36 weeks open-labelRandomized trial · people · 2021
- SS-31 raised muscle ATP capacity after one dose in older adultsRandomized trial · people · 2021
- SS-31: walk distance rose with dose in 5-day MMPOWER trialRandomized trial · people · 2018
- SS-31: less kidney hypoxia after renal artery stenting in pilotRandomized trial · people · 2017
- Every study on SS-31
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.